ImmunityBio surge continues on sign its drug may be approved to treat a broader range of bladder cancers
Once you start squeezing, you can’t put the toothpaste back in the tube. Shares of are flying higher once again, up more than 30% in early trading Tuesday after having been down as much as 10% in the...
Flurry of positive announcements make ImmunityBio the next short squeeze target for retail traders
Heavily shorted is continuing its stellar run, up big in premarket trading after management delivered its fourth and fifth doses of positive news for the week. In a pair of press releases, the biotec...
Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s
Strive Specialties, one of the largest compounding pharmacies in the country, accused and of locking up telehealth companies they partner with in an effort to cut off businesses like them from the G...
Big Pharma enters 2026 with an appetite for deals
CEO Mark Goldsmith, whose company might be at the center of what could wind up being the biggest biotech deal of the year, is staying tight-lipped. His company, a California-based startup working on a...
Moderna rallies after projecting better-than-expected 2025 sales
rallied more than 15% on Tuesday after saying on Monday that its COVID-19 business did better than expected last year and it cut even more costs. Moderna, which has been bleeding money since 2023, als...
Moderna says its expects $1.9 billion in 2025 sales amid better-than-expected vaccination rate
said its COVID-19 business did better than expected last year, driven by lower-than-anticipated declines in vaccination rates despite attacks from the Trump administration. The company expects to repo...
Tempus AI rises on better-than-expected sales numbers
Cancer diagnostics company and retail shareholder favorite surged early Monday after issuing some fresh, though preliminary, financials ahead of an appearance at an investor conference today. The Chi...
Abivax rises amid report Eli Lilly is preparing a €15 billion bid
French biotech rose more than 20% in premarket trading after French outlet La Lettre reported that is preparing a €15 billion bid (or roughly $17.5 billion) for the company. Lilly has yet to submit...
Amazon pharmacy to begin offering home delivery for Novo Nordisk’s Wegovy pill
Pharmacy announced Friday that it will offer recently approved weight-loss pill Wegovy, the newest frontier in the drugmaker’s push toward direct-to-consumer options. Amazon said it will offer delive...
American patients are increasingly turning to AI for medical advice — so are their doctors
With the world weighing up the pitfalls of giving AI access to sensitive personal data, OpenAI just unveiled a service where people can upload medical records directly to its chatbot. On Wednesday, th...
AbbVie says it’s not in talks to buy Revolution Medicines; WSJ reports another suitor may prevail
says it “is not in discussions” to acquire oncology biotech , bucking previous reporting by The Wall Street Journal and sending both stocks slipping in early trading. The Journal reported Wednesday th...
Moderna rallies after BofA raises its price target to $24 from $21
rose on Tuesday after Bank of America analysts raised their price target for the ailing biotech behind the COVID-19 vaccine, painting a rosy picture of the products in its pipeline. BofA kept Moderna’...
Novo Nordisk rallies after FDA weight loss pill approval
US-listed shares are up 7% in pre-market trading on Tuesday after the US Food and Drug Administration approved its Wegovy weight loss pill on Monday evening. Now the first pill of its kind to receive ...
Pfizer falls after 2026 guidance falls short of analysts’ expectations
is lower in early trading after reaffirming its 2025 guidance and giving analysts a fresh steer on 2026. The company said it expects 2026 annual adjusted earnings per share to hit between $2.80 and $3...
Hims slips after US lawmakers introduce bill cracking down on compounding
slipped on Wednesday after members of Congress introduced a bill that would limit its ability to sell copies of blockbuster weight-loss drugs made by and . The bill, “ Safeguarding Americans from Fra...
Structure Therapeutics posts mid-stage weight-loss pill data in line with Eli Lilly rival
soared in early trading after it reported mid-stage results for its weight-loss pill that were roughly in line with competing product. The San Francisco-based biotech reported that patients lost rou...
Hims to acquire blood collection company YourBio
struck a deal to buy blood collection company YourBio, Hims said Wednesday. YourBio makes a device that uses “bladeless microneedles thinner than an eyelash” to collect blood samples painlessly. The a...
Eli Lilly slashes Zepbound vial prices on its direct-to-consumer platform
slashed the cash-pay price for its blockbuster obesity drug as it pushes forward on a pricing war with rival . Lilly said Monday that it would bring down the price for its obesity shot Zepbound throug...
Pfizer’s CFO on building a post-Covid future and how it won the fight for Metsera
is trying to prove it can grow again. After a year of cost-cutting and strategic deals, the drugmaker’s $10 billion purchase of Metsera is just one part of a larger reset, CFO Dave Denton told Sherwoo...
Novo Nordisk’s stock sinks after Ozempic’s key ingredient fails to slow down Alzheimer’s in trials
is down nearly 8% in trading in Europe, with its US-listed ADRs dropping a similar amount, after the pharma giant shared that oral semaglutide — a key ingredient behind its Ozempic and Wegovy drugs — ...